Epidemiology and Vaccine Efficacy of Delta Variant



Abstract Views
309

Downloads
209

Citations

Share

##plugins.themes.bootstrap3.article.sidebar##

Submitted Nov 30, 2021
Published Dec 29, 2021
10.24018/ejmed.2021.3.6.1162

Abstract viewed = 309 times

Table of Contents

##plugins.themes.bootstrap3.article.main##

Several variants of concern (VOCs) of SARS-CoV-2 have emerged after its first outbreak in 2020. These VOCs possess mutations in the spike protein that confers enhanced rate of infection and transmission of these VOCs. Among these VOCs, the delta/B.1.617.2 variant was identified in late 2020 in India and soon spread to several countries around the globe. Currently, it is the most widely sequenced variant among new infected individuals with SARS-CoV-2 infection. This variant is also found to be associated with COVID-19 infection in vaccinated individuals, but the severity of disease and rate of hospitalization are low among these individuals as compared to unvaccinated individuals. With the emergence of new variants of SARS-CoV-2 due to continuous mutations, it is suggested that vaccination plays a significant role in preventing the transmission of disease and disease severity.

Keywords: AstraZeneca, BNT162b2, coronavirus, COVID-19, Delta variant, Moderna and ChAdOx1, mRNA-1273, Pfizer-bioNTech, RNA load, SARS vaccine, SARS-CoV-2, several variants of concern (VOCs), spike protein

Downloads

Download data is not yet available.

References

  1. Nyberg T, Twohig KA, Harris RJ, Seaman SR, Flannagan J, Allen H, et al. Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: Cohort analysis. The BMJ. 2021; 373: 1–10.
    DOI  |   Google Scholar
  2. Fisman DN, Tuite AR. Progressive Increase in Virulence of Novel SARS-CoV-2 Variants in Ontario, Canada. MedRxiv, 2021.
    DOI  |   Google Scholar
  3. O'Toole Á, Hill V, Pybus OG, Watts A, Bogoch II, Khan K, et al. Tracking the international spread of SARS-CoV-2 lineages B. 1.1. 7 and B. 1.351/501Y-V2. Wellcome Open Research. 2021; 6.
     Google Scholar
  4. World Health Organization. WHO Coronavirus (COVID-19) Dashbooard. [Internet] 2021. [cited on November 28, 2021] Available from: https://covid19.who.int.
     Google Scholar
  5. Li B, Deng A, Li K, Hu Y, Li Z, Xiong Q, et al. Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant. MedRxiv, 2021.
    DOI  |   Google Scholar
  6. Shitrit P, Zuckerman NS, Mor O, Gottesman BS, Chowers M. Nosocomial outbreak caused by the SARS-CoV-2 Delta variant in a highly vaccinated population, Israel, July 2021. Eurosurveillance. 2021; 26(39).
    DOI  |   Google Scholar
  7. Chia PY, Ong SWX, Chiew CJ, Ang LW, Chavatte J-M, Mak T-M., et al. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study. Clinical Microbiology and Infection. 2021.
    DOI  |   Google Scholar
  8. Nasreen S, Chung H, He S, Brown KA, Gubbay JB, Buchan SA, et al. Effectiveness of mRNA and ChAdOx1 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario. MedRxiv, 2021.
    DOI  |   Google Scholar
  9. Tuite AR, Fisman DN, Odutayo A, Bobos P, Allen V, Bogoch II, et al. COVID - 19 Hospitalizations, ICU Admissions and Deaths Associated with the New Variants of Concern. Science Briefs of the Ontario COVID-19 Science Advisory Table. 2021; 1(18): 1–10.
    DOI  |   Google Scholar
  10. Cherian S, Potdar V, Jadhav S, Yadav P, Gupta N, Das M, et al. The Second Wave of COVID-19 in Maharashtra , India. Microorganism. 2021; 2: 1–11.
     Google Scholar
  11. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. New England Journal of Medicine. 2021; 385(7): 585–594.
    DOI  |   Google Scholar
  12. Centers for Disease Control and Prevention. COVID Data Tracker. [Internet] 2021. [cited on November 29, 2021] Available from: https://covid.cdc.gov/covid-data-tracker
     Google Scholar
  13. Mlcochova P, Kemp S, Dhar MS, Papa G, Meng B, Ferreira IATM, et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature. 2021; 599(November).
     Google Scholar
  14. Kuppalli K, Gala P, Cherabuddi K, Kalantri SP, Mohanan M, Mukherjee B, et al. India’s COVID-19 crisis: a call for international action. The Lancet. 2021; 397(10290): 2132–2135.
    DOI  |   Google Scholar
  15. Mishra S, Mindermann S, Sharma M, Whittaker C, Mellan TA, Wilton T, et al. Changing composition of SARS-CoV-2 lineages and rise of Delta variant in England. EClinicalMedicine. 2021; 39: 1–8.
    DOI  |   Google Scholar
  16. Organization PAH. (2021, October 14). Epidemiological update: Coronavirus disease (covid-19) [Internet] 2014. [cited on November 24, 2021] Available from: https://iris.paho.org/handle/10665.2/54997.
     Google Scholar
  17. Gallo Marin B, Aghagoli G, Lavine K, Yang L, Siff EJ, Chiang SS, et al. Predictors of COVID‐19 severity: A literature review. Reviews in Medical Virology. 2021; 31(1): 1-10.
    DOI  |   Google Scholar
  18. Twohig KA, Nyberg T, Zaidi A, Thelwall S, Sinnathamby MA, Aliabadi S, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infect Dis. 2021.
     Google Scholar
  19. Sheikh A, McMenamin J, Taylor B, Robertson, C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet (London, England). 2021; 397(10293): 2461–2462.
    DOI  |   Google Scholar